861839-97-6

Upstream product

• 52178-50-4 Methyl 3-formylbenzoate 
• 913722-59-5 (Z)-methyl 3-(2-nitroprop-1-enyl)benzoate 
• 131671-68-6 3-(2-nitro-propenyl)-benzoic acid methyl ester 

Downstream Products

• 881208-15-7 tert-butyl-6-((2-(1-(3-(hydroxymethyl)phenyl)propan-2-ylamino)pyrimidin-4-yl)(methyl)amino)-2-phenylpyrimidin-4-ylcarbamate 
• 872059-25-1 C₂₇H₂₇N₇O 
• 861840-07-5 2-{2-[2-(3-hydroxymethyl-phenyl)-1-methyl-ethylamino]-pyrimidin-4-ylamino}-3-methyl-6-phenyl-3H-pyrimidin-4-one 
• 861839-35-2 9-(2-{(1-methyl-2-(3-(hydroxymethyl)phenyl)-ethyl)amino}-pyrimidin-4-yl)-2-phenyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one 

Relevant academic research and scientific papers

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to compounds having the general structure: (I) and pharmaceutically acceptable salts and hydrates thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple m

Substituted heterocyclic compounds and methods of use

The present invention relates to compounds having the general structure: and pharmaceutically acceptable salts and hydrates thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myelo

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to pyrimidinones and pyridones and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic ? cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

Method and reagents for detecting amphetamine and/or d-methamphetamine in biological samples

This disclosure relates to a method and reagents for determining amphetamine and d-methamphetamine in a biological fluid, such as urine. In particular, this disclosure relates to improvements in a fluorescence polarization immunoassay procedure for determining the presence of amphetamine and d-methamphetamine in a single assay and to a novel class of tracer compounds employed as reagents in such procedures. The procedure described includes pretreatment of the biological sample to eliminate cross-reactants such as β-hydroxyphenethylamine by preincubating the sample solely with an aqueous periodate solution having a pH from about 4.0 to about 7.5 without adjustment to an alkaline pH, and contacting the sample with riboflavin binding protein to reduce interference from fluorescent components in the sample. The procedure also maintains the cross reactivity of the immunoassay for tyramine at about 0.4% and for l-methamphetamine below about 5.1% and eliminates the necessity of using controlled substances as starting materials.